Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This surveillance's objectives are

1. Unknown adverse reactions

2. Incidences of adverse drug reaction

3. Efficacy during long-term administration

4. Factors considered to have effect to safety and effectiveness

5. Incidences of status epileptics, skin disorders and hyper sensitivity reaction, and central nervous system-related adverse events(ataxia , somnolence and/or dizzy, etc.)

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eisai Co., Ltd.
• Treatments: Rufinamide

Criteria

All patients with Lennox-Gastaut syndrome and administrated Inovelon